Clinical Trials
29 trialsHAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
Sun Yat-sen University
ARTEMIDE-HCC01
AstraZeneca
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
UPGRADE
First Affiliated Hospital, Sun Yat-Sen University
Adjuvant TACE in HCC With High-risk Recurrence Factors
Guangxi Medical University
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
Polaris Group
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Continuation of First-line Therapy With Radiotherapy Versus Early Switch to Second-line Therapy in Oligoprogressive HCC
Shandong Cancer Hospital and Institute
MOIO
UNICANCER
MRD-GI
Georgetown University
LIVERATION
Can-Fite BioPharma
A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection
Akeso
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
Akeso
TACE
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
TREMENDOUS
AstraZeneca
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
Second Affiliated Hospital of Guangzhou Medical University
The ABC-HCC Trial: Atezolizumab Plus Bevacizumab vs. Transarterial Chemoembolization (TACE) in Intermediate-stage HepatoCellular Carcinoma
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
The First Affiliated Hospital with Nanjing Medical University
HAIC
Sun Yat-sen University
Clinical Outcome and Future Liver Remnant Regenerative Response in Laparoscopic Versus Open ALPPS
The University of Hong Kong
BESTPOP
Beijing Shenogen Biomedical Co., Ltd
Zinc Supplementation to Improve Prognosis in Patients With Compensated Advanced Chronic Liver Disease.
Hospital Universitari Vall d'Hebron Research Institute
FOLFOX-HAIC Plus Lenvatinib and Toripalimab vs. FOLFOX-HAIC Plus Lenvatinib for Advanced Hepatocellular Carcinoma: a Randomized Controlled and Double-blind Trial
Sun Yat-sen University
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Second Affiliated Hospital of Guangzhou Medical University
Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
HAIC With One-day FOLFOX vs. HAIC With Two-day FOLFOX for Unresectable HCC: a Non-inferiority Study
Sun Yat-sen University
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
Second Affiliated Hospital of Guangzhou Medical University
Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma Beyond Milan/UCSF Criteria Who Underwent Liver Transplantation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The Impact on Survival of Neo-adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) Who Underwent Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
Sun Yat-sen University